| 產品名稱 |
HPAF-II |
| 商品貨號 |
B164645 |
| Organism |
Homo sapiens, human |
| Tissue |
pancreas |
| Product Format |
frozen |
| Morphology |
epithelial |
| Culture Properties |
adherent |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
adenocarcinoma |
| Age |
44 years |
| Gender |
male |
| Ethnicity |
Caucasian |
| Storage Conditions |
liquid nitrogen vapor phase |
| Derivation |
HPAF-II is a human pancreatic adenocarcinoma cell line derived from peritoneal ascitic fluid of a 44 year old Caucasian male with primary pancreatic adenocarcinoma and metastases to the liver, diaphragm and lymph nodes.- |
| Clinical Data |
Caucasian
44 years
male |
| Antigen Expression |
Blood Type A; Rh-; HLA A1, A10 (W34), B8, W22, Cw3 |
| Genes Expressed |
mucin |
| Cellular Products |
mucin |
| Tumorigenic |
Yes |
| Effects |
Yes, the cells form well differentiated adenocarcinomas in athymic mice which resemble the original tumor |
| Comments |
HPAF II is a spontaneous variant with unlimited replicative capability which proliferated from a static culture of HPAF-I cells. The cells express Muc 1 and Muc 4 mucin genes, and secrete high levels of Muc 1 mucin. They are pleomorphic and probably undergo some spontaneous differentiation in culture.
|
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
| Subculturing |
Volumes are given for a 75 cm2 flask. Increase or decrease the amount of dissociation medium needed proportionally for culture vessels of other sizes.
- Remove and discard culture medium.
- Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
- Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
- Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
- Add appropriate aliquots of the cell suspension to new culture vessels.
- Incubate cultures at 37°C.
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:3 is recommended
Medium Renewal: 2 to 3 times per week |
| Cryopreservation |
Freeze Medium: Complete growth medium 95%; DMSO, 5%
Storage Temperature: Liquid nitrogen vapor phase |
| Culture Conditions |
Temperature: 37°C |
| STR Profile |
Amelogenin: X CSF1PO: 10,11 D13S317: 12 D16S539: 11,13 D5S818: 11,13 D7S820: 10,13 F13A01: 5,17 F13B: 8,10 FESFPS: 11,12 LPL: 10 THO1: 9 TPOX: 8 vWA: 17 |
| Name of Depositor |
RS Metzgar |
| Deposited As |
Homo sapiens |
| References |
Monoclonal antibodies in cancer. Clifton, NJ: Humana Press; 1985.
Monoclonal antibodies and cancer therapy. New York: Liss; 1985.
Immunity to cancer II. New York: Liss; 1989.
Metzgar RS, et al. Antigens of human pancreatic adenocarcinoma cells defined by murine monoclonal antibodies. Cancer Res. 42: 601-608, 1982. PubMed: 7034925
Kim YW, et al. Characterization of clones of a human pancreatic adenocarcinoma cell line representing different stages of differentiation. Pancreas 4: 353-362, 1989. PubMed: 2734279
Mullins TD, et al. Ultrastructural differentiation of sodium butyrate-treated human pancreatic adenocarcinoma cell lines. Pancreas 6: 578-587, 1991. PubMed: 1946315
Worlock AJ, et al. Radiolocalization of human pancreatic tumors in athymic mice by monoclonal antibody DU-PAN 1. Cancer Res. 50: 7246-7251, 1990. PubMed: 2224857
|
